Author:
Ding Yangyang,Huang Keke,Sun Cheng,Liu Zelin,Zhu Jinli,Jiao Xunyi,Liao Ya,Feng Xiangjiang,Guo Jingjing,Zhu Chunhua,Zhai Zhimin,Xiong Shudao
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Sabattini, E., Bacci, F., Sagramoso, C. & Pileri, S. A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica 102(3), 83–87 (2010).
2. Tilly, H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol 26(Suppl 5), v116–v125 (2015).
3. Klener, P. & Klanova, M. Drug resistance in non-Hodgkin lymphomas. Int. J. Mol. Sci. 21(6), 2081 (2020).
4. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol. Cancer 17(1), 57 (2018).
5. Cheng, S. et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28(3), 649–657 (2014).